Laman UtamaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$4.32
Julat hari
$4.32 - $4.70
Julat tahun
$3.32 - $12.70
Permodalan pasaran
178.36J USD
Bilangan Purata
2.52K
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CHF) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 0.00 | -100.00% |
Perbelanjaan pengendalian | 52.85J | 815.93% |
Pendapatan bersih | -11.23J | 43.22% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.30 | — |
EBITDA | -14.22J | 13.35% |
Kadar cukai berkesan | -0.02% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CHF) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 149.44J | -20.04% |
Jumlah aset | 158.53J | -20.08% |
Jumlah liabiliti | 16.89J | -22.95% |
Jumlah ekuiti | 141.64J | — |
Syer tertunggak | 36.71J | — |
Harga kepada buku | 1.12 | — |
Pulangan pada aset | -23.65% | — |
Pulangan pada modal | -25.90% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CHF) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -11.23J | 43.22% |
Tunai daripada operasi | -13.20J | 17.47% |
Tunai daripada pelaburan | -4.49J | -123.10% |
Tunai daripada pembiayaan | 15.30J | 5,234.56% |
Perubahan bersih dalam tunai | -1.88J | -72.29% |
Aliran tunai bebas | -12.16J | -29.92% |
Perihal
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Diasaskan
2004
Tapak web
Pekerja
162
